Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia.

Kapidzic A, van der Meulen MP, Hol L, van Roon AH, Looman CW, Lansdorp-Vogelaar I, van Ballegooijen M, van Vuuren AJ, Reijerink JC, van Leerdam ME, Kuipers EJ.

Clin Gastroenterol Hepatol. 2015 Feb 24. pii: S1542-3565(15)00162-7. doi: 10.1016/j.cgh.2015.02.023. [Epub ahead of print]

PMID:
25724706
2.

Repeated screening with fecal immunochemical tests reduced the incidence of colorectal cancers in Saga, Japan.

Sakata N, Sakata Y, Shimoda R, Sakata H, Iwakiri R, Fujimoto K, Mizuguchi M, Irie H, Shimoda Y, Noshiro H.

Hepatogastroenterology. 2014 Jul-Aug;61(133):1224-8.

PMID:
25436287
3.

[Colorectal cancer screening: a work in progress].

Bretagne JF.

Presse Med. 2014 Nov;43(11):1165-7. doi: 10.1016/j.lpm.2014.08.004. Epub 2014 Sep 26. French. No abstract available.

PMID:
25261917
4.

Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.

Chausserie S, Levillain R, Puvinel J, Ferrand O, Ruiz A, Raginel T, Lantieri O, Launoy G, Guittet L.

Int J Cancer. 2015 Apr 15;136(8):1827-34. doi: 10.1002/ijc.29187. Epub 2014 Sep 18.

PMID:
25195670
5.

The psychological impact of participating in colorectal cancer screening by faecal immuno-chemical testing--the Australian experience.

Bobridge A, Bampton P, Cole S, Lewis H, Young G.

Br J Cancer. 2014 Aug 26;111(5):970-5. doi: 10.1038/bjc.2014.371. Epub 2014 Jul 1.

PMID:
24983363
6.

Attendance and yield over three rounds of population-based fecal immunochemical test screening.

Kapidzic A, Grobbee EJ, Hol L, van Roon AH, van Vuuren AJ, Spijker W, Izelaar K, van Ballegooijen M, Kuipers EJ, van Leerdam ME.

Am J Gastroenterol. 2014 Aug;109(8):1257-64. doi: 10.1038/ajg.2014.168. Epub 2014 Jul 1.

PMID:
24980879
7.

Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.

Hillyer GC, Schmitt KM, Freedberg DE, Kramer RA, Su Y, Rosenberg RM, Neugut AI.

Am J Prev Med. 2014 Aug;47(2):182-7. doi: 10.1016/j.amepre.2014.03.011. Epub 2014 Jun 17.

8.

Population-based screening in colorectal cancer - current practice and future developments: faecal biomarkers review.

Sawbridge D, Probert C.

J Gastrointestin Liver Dis. 2014 Jun;23(2):195-202. Review.

9.

Colorectal cancer: from prevention to personalized medicine.

Binefa G, Rodríguez-Moranta F, Teule A, Medina-Hayas M.

World J Gastroenterol. 2014 Jun 14;20(22):6786-808. doi: 10.3748/wjg.v20.i22.6786. Review.

10.

Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.

Auge JM, Pellise M, Escudero JM, Hernandez C, Andreu M, Grau J, Buron A, López-Cerón M, Bessa X, Serradesanferm A, Piracés M, Macià F, Guayta R, Filella X, Molina R, Jimenez W, Castells A; PROCOLON Group.

Gastroenterology. 2014 Sep;147(3):628-636.e1. doi: 10.1053/j.gastro.2014.06.008. Epub 2014 Jun 14.

PMID:
24937264
11.

KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.

Battaglia P, Baritono E, Remo A, Vendraminelli R, Conti A.

Tumori. 2014 Mar-Apr;100(2):122-7. doi: 10.1700/1491.16391.

PMID:
24852854
12.

Patient perceptions of stool DNA testing for pan-digestive cancer screening: a survey questionnaire.

Yang D, Hillman SL, Harris AM, Sinicrope PS, Devens ME, Ahlquist DA.

World J Gastroenterol. 2014 May 7;20(17):4972-9. doi: 10.3748/wjg.v20.i17.4972.

13.

Tests and investigations for colorectal cancer screening.

Carroll MR, Seaman HE, Halloran SP.

Clin Biochem. 2014 Jul;47(10-11):921-39. doi: 10.1016/j.clinbiochem.2014.04.019. Epub 2014 Apr 24. Review.

PMID:
24769265
14.

Current and future molecular diagnostics in colorectal cancer and colorectal adenoma.

Tsang AH, Cheng KH, Wong AS, Ng SS, Ma BB, Chan CM, Tsui NB, Chan LW, Yung BY, Wong SC.

World J Gastroenterol. 2014 Apr 14;20(14):3847-57. doi: 10.3748/wjg.v20.i14.3847. Review.

15.

Colorectal cancer screening: 20 years of development and recent progress.

Zavoral M, Suchanek S, Majek O, Fric P, Minarikova P, Minarik M, Seifert B, Dusek L.

World J Gastroenterol. 2014 Apr 14;20(14):3825-34. doi: 10.3748/wjg.v20.i14.3825. Review.

16.

A workplace colorectal cancer screening program in firefighters: lessons learned.

Walsh JM, Potter MB, Arora M, Gildegorin G, Terdiman J.

Occup Med (Lond). 2014 Jun;64(4):255-8. doi: 10.1093/occmed/kqu046. Epub 2014 Apr 17.

PMID:
24744344
17.

Comparison of fecal occult blood tests for colorectal cancer screening in an Alaska Native population with high prevalence of Helicobacter pylori infection, 2008-2012.

Redwood D, Provost E, Asay E, Roberts D, Haverkamp D, Perdue D, Bruce MG, Sacco F, Espey D.

Prev Chronic Dis. 2014 Apr 10;11:E56. doi: 10.5888/pcd11.130281.

18.

To foster screening, new colon cancer tests emphasize convenience.

Willyard C.

Nat Med. 2014 Apr;20(4):322-3. doi: 10.1038/nm0414-322. No abstract available.

PMID:
24710365
19.

Multitarget stool DNA testing for colorectal-cancer screening.

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM.

N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.

20.

Diagnostic value of fecal calprotectin as a screening biomarker for gastrointestinal malignancies.

Khoshbaten M, Pishahang P, Nouri M, Lashkari A, Alizadeh M, Rostami-Nejad M.

Asian Pac J Cancer Prev. 2014;15(4):1667-70.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk